Search
Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalTividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099 … Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout
Synonyms: L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T 676>S,Josamycin
go.drugbank.com/drugs/DB01321InvestigationalA macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseTiaprofenic acid
go.drugbank.com/drugs/DB01600ApprovedTiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain.
Albumin Aggregated
go.drugbank.com/drugs/DB14230ApprovedAlbumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection. … [L12816] This imaging agent is used to assess lung perfusion and for the evaluation of peritoneovenous (LeVeen) shunt patency.
Perphenazine
go.drugbank.com/drugs/DB00850ApprovedInvestigationalAn antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Sulopenem etzadroxil
go.drugbank.com/drugs/DB16335ApprovedInvestigationalSulopenem etzadroxil is a prodrug of the penem antibacterial [sulopenem]. Like other beta-lactam antibacterials, it is a time-dependent inhibitor of bacterial cell wall synthesis. … [L51858] It is administered in combination with [probenecid] in order to increase antibiotic exposure.[L51768]
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
Axitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalIt is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative. … [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawnNalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist. … [L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspected opioid overdose.